Can Targeting Non-Neuronal Cells Improve Cancer Therapy?
Yes, targeting non-neuronal cells in the TME has shown promise in improving cancer therapies. For example:
- Anti-angiogenic therapies aim to inhibit blood vessel formation, starving the tumor of nutrients. - Immunotherapies such as checkpoint inhibitors re-activate the immune system to attack cancer cells. - CAF-targeting drugs aim to disrupt the supportive role of fibroblasts in cancer progression.
